ES2523740T3 - Anticuerpos monoclonales para el receptor del factor de crecimiento de fibroblastos 2 - Google Patents

Anticuerpos monoclonales para el receptor del factor de crecimiento de fibroblastos 2 Download PDF

Info

Publication number
ES2523740T3
ES2523740T3 ES09825523.5T ES09825523T ES2523740T3 ES 2523740 T3 ES2523740 T3 ES 2523740T3 ES 09825523 T ES09825523 T ES 09825523T ES 2523740 T3 ES2523740 T3 ES 2523740T3
Authority
ES
Spain
Prior art keywords
cdr
receptor
growth factor
fibroblast growth
monoclonal antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09825523.5T
Other languages
English (en)
Spanish (es)
Inventor
Kyung Jin Kim
Wei-Meng Zhao
Hangil Park
Maximiliano Vasquez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galaxy Biotech LLC
Original Assignee
Galaxy Biotech LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galaxy Biotech LLC filed Critical Galaxy Biotech LLC
Application granted granted Critical
Publication of ES2523740T3 publication Critical patent/ES2523740T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES09825523.5T 2008-11-07 2009-11-06 Anticuerpos monoclonales para el receptor del factor de crecimiento de fibroblastos 2 Active ES2523740T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11268608P 2008-11-07 2008-11-07
US112686P 2008-11-07
US16487009P 2009-03-30 2009-03-30
US164870P 2009-03-30
PCT/US2009/063647 WO2010054265A2 (en) 2008-11-07 2009-11-06 Monoclonal antibodies to fibroblast growth factor receptor 2

Publications (1)

Publication Number Publication Date
ES2523740T3 true ES2523740T3 (es) 2014-12-01

Family

ID=42153600

Family Applications (3)

Application Number Title Priority Date Filing Date
ES14188785.1T Active ES2646168T3 (es) 2008-11-07 2009-11-06 Anticuerpos monoclonales para el receptor del factor de crecimiento de fibroblastos 2
ES17191118T Active ES2770134T3 (es) 2008-11-07 2009-11-06 Anticuerpos monoclonales para el receptor del factor de crecimiento de fibrolastos 2
ES09825523.5T Active ES2523740T3 (es) 2008-11-07 2009-11-06 Anticuerpos monoclonales para el receptor del factor de crecimiento de fibroblastos 2

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ES14188785.1T Active ES2646168T3 (es) 2008-11-07 2009-11-06 Anticuerpos monoclonales para el receptor del factor de crecimiento de fibroblastos 2
ES17191118T Active ES2770134T3 (es) 2008-11-07 2009-11-06 Anticuerpos monoclonales para el receptor del factor de crecimiento de fibrolastos 2

Country Status (20)

Country Link
US (8) US8101723B2 (OSRAM)
EP (4) EP2365828B1 (OSRAM)
JP (8) JP5627591B2 (OSRAM)
KR (1) KR101699432B1 (OSRAM)
CN (1) CN102131524B (OSRAM)
AU (1) AU2009313357B2 (OSRAM)
BR (1) BRPI0917315B8 (OSRAM)
CA (2) CA2733668C (OSRAM)
DK (3) DK2365828T3 (OSRAM)
ES (3) ES2646168T3 (OSRAM)
HR (2) HRP20171640T1 (OSRAM)
HU (1) HUE035700T2 (OSRAM)
LT (2) LT3290052T (OSRAM)
MX (1) MX2011000455A (OSRAM)
NO (1) NO2842573T3 (OSRAM)
PL (3) PL2842573T3 (OSRAM)
PT (3) PT3290052T (OSRAM)
RU (1) RU2546254C9 (OSRAM)
SI (2) SI3290052T1 (OSRAM)
WO (1) WO2010054265A2 (OSRAM)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9260525B2 (en) 2008-02-04 2016-02-16 Xiao-Jia Chang Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
WO2012021841A2 (en) * 2010-08-12 2012-02-16 Attogen Inc. Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
WO2009100105A2 (en) * 2008-02-04 2009-08-13 Attogen Inc. Inhibitors of oncogenic isoforms and uses thereof
JP5627591B2 (ja) 2008-11-07 2014-11-19 ギャラクシー バイオテック， エルエルシー 線維芽増殖因子受容体２に対するモノクローナル抗体
CA2800311A1 (en) * 2010-05-11 2011-11-17 Aveo Pharmaceuticals, Inc. Anti-fgfr2 antibodies
JP6400470B2 (ja) 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド 多重特異性Ｆａｂ融合タンパク質および使用法
AR088941A1 (es) 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
JP2015505850A (ja) * 2011-12-14 2015-02-26 シアトル ジェネティックス， インコーポレイテッド 新規な抗体薬物コンジュゲート（ａｄｃ）およびそれらの使用
DK2822968T3 (en) 2012-03-08 2018-04-16 Janssen Vaccines & Prevention Bv HUMAN BINDING MOLECULES ABLE TO BIND AND NEUTRALIZE INFLUENZA-B-VIRA, AND APPLICATIONS THEREOF
JP6188681B2 (ja) * 2012-04-09 2017-08-30 第一三共株式会社 抗ｆｇｆｒ２抗体
WO2014089193A1 (en) * 2012-12-04 2014-06-12 Aveo Pharmaceuticals, Inc. Anti-fgfr2 antibodies
AU2013362937A1 (en) * 2012-12-21 2015-07-02 Janssen Biotech, Inc. Sensitive multiplex immunoassay for soluble fibroblast growth factor receptors
CN103145843B (zh) * 2013-02-20 2014-10-29 暨南大学 抗成纤维细胞生长因子受体的单链抗体
MX2015011428A (es) 2013-03-06 2016-02-03 Genentech Inc Metodos para tratar y prevenir la resistencia a los farmacos para el cancer.
NZ715201A (en) * 2013-08-01 2021-12-24 Five Prime Therapeutics Inc Afucosylated anti-fgfr2iiib antibodies
JP6509735B2 (ja) * 2013-10-08 2019-05-08 第一三共株式会社 抗ｆｇｆｒ２抗体と他剤の組合せ
CN103757026B (zh) * 2013-12-20 2017-04-05 广州圣露生物技术有限公司 FGFR2b胞外段的基因序列、多肽及其应用
CN107073121A (zh) 2014-06-13 2017-08-18 基因泰克公司 治疗及预防癌症药物抗性的方法
CN104231079A (zh) * 2014-09-12 2014-12-24 暨南大学 一种靶向bFGF高亲和力受体结合位点的抗体及其应用
TW201642904A (zh) * 2015-04-08 2016-12-16 第一三共股份有限公司 含抗ｆｇｆｒ２抗體及其他藥劑之組成物
WO2016171107A1 (ja) * 2015-04-20 2016-10-27 第一三共株式会社 Ｆｇｆｒ２の検出
RU2638457C2 (ru) * 2015-09-28 2017-12-13 Общество С Ограниченной Ответственностью "Онкомакс" Антитела, специфически связывающие рецептор 1 типа фактора роста фибробластов, применение антител для лечения онкологического заболевания, способ получения антител
CA3004794A1 (en) * 2015-11-23 2017-06-01 Five Prime Therapeutics, Inc. Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
AU2017233121B2 (en) 2016-03-15 2023-12-21 Itabmed (Hk) Limited Multispecific Fab fusion proteins and use thereof
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
SG10202112636SA (en) 2017-05-16 2021-12-30 Five Prime Therapeutics Inc Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
US11603401B2 (en) 2017-06-02 2023-03-14 Ablynx N.V. Aggrecan binding immunoglobulins
JP7280254B2 (ja) 2017-10-24 2023-05-23 マジェンタ セラピューティクス インコーポレイテッド Ｃｄ１１７＋細胞を減少させるための組成物及び方法
WO2019084067A1 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. ANTI-CD117 ANTIBODIES AND METHODS OF USE
TW201922782A (zh) 2017-10-24 2019-06-16 美商麥珍塔治療學股份有限公司 去除cd117+細胞之組合物及方法
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
CN112804989A (zh) 2018-10-05 2021-05-14 戊瑞治疗有限公司 抗fgfr2抗体制剂
CA3160812A1 (en) * 2019-12-24 2021-07-01 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Novel anti-fgfr2b antibodies
CA3160811A1 (en) * 2019-12-24 2021-07-01 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Novel anti-fgfr2b antibodies
EP4161566A4 (en) * 2020-06-03 2024-06-12 The Broad Institute, Inc. ANTAGONISTIC BIPARATOPIC ANTIBODIES THAT SPECIFICALLY BIND FIBROBLAST GROWTH FACTOR RECEPTOR 2 AND METHODS OF USE THEREOF
EP4232481A1 (en) 2020-10-22 2023-08-30 Regeneron Pharmaceuticals, Inc. Anti-fgfr2 antibodies and methods of use thereof
US20240101683A1 (en) * 2020-12-29 2024-03-28 Shenzhen Forward Pharmaceuticals Co., Limited Anti-FGFR2 Antibody and Use Thereof
EP4414387A4 (en) * 2021-10-08 2025-10-29 Shenzhen Forward Pharmaceuticals Co Ltd ANTI-FGFR2 ANTIBODY WITH IMPROVED ADCC AND ITS USE
TW202342527A (zh) 2022-02-25 2023-11-01 美商安進公司 鱗狀非小細胞肺癌之治療
KR20250099773A (ko) * 2022-09-30 2025-07-02 3에이치 파머슈티컬즈 컴퍼니 리미티드 항-fgfr2b 항체 및 이의 용도
TW202442685A (zh) * 2023-04-28 2024-11-01 大陸商武漢人福創新藥物研發中心有限公司 抗FGFR2b單抗
WO2024240107A1 (zh) * 2023-05-19 2024-11-28 广东东阳光药业股份有限公司 一种抗fgfr2抗体及其应用
WO2024255756A1 (zh) * 2023-06-13 2024-12-19 南京维立志博生物科技股份有限公司 基于共同轻链产生双特异性抗体的方法
TW202527998A (zh) * 2023-12-18 2025-07-16 大陸商山東先聲生物製藥有限公司 抗FGFR2b抗體-藥物綴合物及其應用
WO2025218662A1 (zh) * 2024-04-16 2025-10-23 杭州中美华东制药有限公司 抗成纤维细胞生长因子受体2b的抗体及其用途
WO2025232811A1 (zh) * 2024-05-09 2025-11-13 正大天晴药业集团股份有限公司 靶向成纤维细胞生长因子受体2IIIb的抗体及其应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU638734B2 (en) 1989-07-06 1993-07-08 Regents Of The University Of California, The Receptors for fibroblast growth factors
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5863888A (en) 1990-07-06 1999-01-26 Rhone-Poulenc Rorer Pharmaceuticals Inc. Human Bek Fibroblast growth factor receptor
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5620889A (en) * 1993-10-14 1997-04-15 Immunex Corporation Human anti-Fas IgG1 monoclonal antibodies
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6323316B1 (en) 1996-06-18 2001-11-27 The United States Of America As Represented By The Secretary Of The Department Of And Human Services Fibroblast growth factor receptor activating gene 1 and related compositions and methods
US20030143676A1 (en) * 1999-03-25 2003-07-31 Genesis Research And Development Corporation Limited Fibroblast growth factor receptors and methods for their use
WO2000064946A2 (en) * 1999-04-28 2000-11-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
JP2001302699A (ja) 2000-04-17 2001-10-31 Nichirei Corp ヒトｋｇｆｒに対する抗体
US20020115603A1 (en) 2000-06-22 2002-08-22 Chiron Corporation Methods and compositions for the treatment of peripheral artery disease
KR100945108B1 (ko) * 2001-06-13 2010-03-02 젠맵 에이/에스 표피 성장 인자 수용체 (ｅｇｆｒ)에 대한 인간모노클로날 항체
IL159177A0 (en) 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
WO2003063893A2 (en) 2002-01-31 2003-08-07 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Fgfr agonists
KR100493460B1 (ko) * 2002-08-29 2005-06-07 재단법인서울대학교산학협력재단 암 세포에서 발현되는 ｆｇｆｒ2 이성체
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
EP2341067A1 (en) 2003-07-18 2011-07-06 Amgen, Inc Specific binding agents to hepatocyte growth factor
US20070248605A1 (en) * 2003-12-19 2007-10-25 Five Prime Therapetutics, Inc. Fibroblast Growth Factor Receptors 1,2,3, and 4 as Targets for Therapeutic Intervention
WO2005115363A2 (en) 2004-05-25 2005-12-08 Yale University Method for treating skeletal disorders resulting from fgfr malfunction
WO2007114896A2 (en) 2006-03-31 2007-10-11 Ordway Research Institute Prognostic and diagnostic method for cancer therapy
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
WO2007134210A2 (en) * 2006-05-12 2007-11-22 Genentech, Inc. Methods and compositions for the diagnosis and treatment of cancer
NZ573818A (en) 2006-06-02 2011-09-30 Aveo Pharmaceuticals Inc Hepatocyte growth factor (hgf) binding proteins
NZ573819A (en) 2006-06-02 2011-09-30 Aveo Pharmaceuticals Inc Hepatocyte growth factor (hgf) binding proteins
CA2655504A1 (en) 2006-06-15 2007-12-21 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
ME02371B (me) 2006-09-29 2016-06-20 Oncomed Pharm Inc Sastojci i postupci za dijagnstikovanje i tretman raka
EP2094733A1 (en) * 2006-11-03 2009-09-02 U3 Pharma GmbH Fgfr4 antibodies
ES2600882T3 (es) * 2007-03-23 2017-02-13 The Translational Genomics Research Institute Procedimiento de clasificación del cáncer de endometrio
US20110091473A1 (en) 2007-10-22 2011-04-21 Genmab A/S Novel antibody therapies
WO2009100105A2 (en) 2008-02-04 2009-08-13 Attogen Inc. Inhibitors of oncogenic isoforms and uses thereof
EP2177615A1 (en) 2008-10-10 2010-04-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
JP5627591B2 (ja) 2008-11-07 2014-11-19 ギャラクシー バイオテック， エルエルシー 線維芽増殖因子受容体２に対するモノクローナル抗体
US20120301482A1 (en) 2009-08-25 2012-11-29 National Jewish Health Methods and compositions for treatment of lung injury

Also Published As

Publication number Publication date
US20180094063A1 (en) 2018-04-05
JP2023116746A (ja) 2023-08-22
CA3166399A1 (en) 2010-05-14
US8101723B2 (en) 2012-01-24
JP6445496B2 (ja) 2018-12-26
JP2020096615A (ja) 2020-06-25
MX2011000455A (es) 2011-02-25
RU2546254C9 (ru) 2015-07-10
US20190153105A1 (en) 2019-05-23
US20100196364A1 (en) 2010-08-05
LT3290052T (lt) 2020-02-25
EP2842573A1 (en) 2015-03-04
JP6342223B2 (ja) 2018-06-13
US10138301B2 (en) 2018-11-27
BRPI0917315B8 (pt) 2021-05-25
PT2842573T (pt) 2017-12-04
RU2011141890A (ru) 2013-04-27
KR101699432B1 (ko) 2017-01-24
LT2842573T (lt) 2017-12-11
PT3290052T (pt) 2020-02-06
EP2842573B1 (en) 2017-09-27
NO2842573T3 (OSRAM) 2018-02-24
US20160362496A1 (en) 2016-12-15
PL2842573T3 (pl) 2018-04-30
HUE035700T2 (en) 2018-05-28
JP6661734B2 (ja) 2020-03-11
JP7301106B2 (ja) 2023-06-30
HRP20200090T1 (hr) 2020-04-03
US10689448B2 (en) 2020-06-23
US9382324B2 (en) 2016-07-05
JP6960485B2 (ja) 2021-11-05
JP2012508184A (ja) 2012-04-05
WO2010054265A3 (en) 2010-09-16
SI2842573T1 (en) 2018-01-31
BRPI0917315B1 (pt) 2020-12-08
EP3290052B1 (en) 2019-12-25
JP2017019807A (ja) 2017-01-26
JP2025032085A (ja) 2025-03-11
ES2646168T3 (es) 2017-12-12
JP2019052165A (ja) 2019-04-04
US8603987B2 (en) 2013-12-10
JP2022008996A (ja) 2022-01-14
HK1160012A1 (en) 2012-08-10
HK1207974A1 (en) 2016-02-19
KR20110081141A (ko) 2011-07-13
AU2009313357B2 (en) 2015-06-11
CA2733668C (en) 2022-08-30
PT2365828E (pt) 2014-12-12
US20200347141A1 (en) 2020-11-05
EP3783024A1 (en) 2021-02-24
BRPI0917315A2 (pt) 2015-11-17
PL2365828T3 (pl) 2015-04-30
DK2365828T3 (en) 2014-12-08
US20230242650A1 (en) 2023-08-03
EP2365828A4 (en) 2012-06-06
JP2014240385A (ja) 2014-12-25
US20120134994A1 (en) 2012-05-31
DK2842573T3 (en) 2017-10-30
SI3290052T1 (sl) 2020-07-31
DK3290052T3 (da) 2020-02-03
CA2733668A1 (en) 2010-05-14
HRP20171640T1 (hr) 2018-01-12
US20140193899A1 (en) 2014-07-10
ES2770134T3 (es) 2020-06-30
RU2546254C2 (ru) 2015-04-10
AU2009313357A1 (en) 2010-05-14
EP2365828A2 (en) 2011-09-21
JP5627591B2 (ja) 2014-11-19
CN102131524B (zh) 2014-05-14
EP3290052A1 (en) 2018-03-07
EP2365828B1 (en) 2014-10-15
PL3290052T3 (pl) 2020-06-29
US9834609B2 (en) 2017-12-05
HK1249053A1 (en) 2018-10-26
WO2010054265A2 (en) 2010-05-14
CN102131524A (zh) 2011-07-20

Similar Documents

Publication Publication Date Title
ES2523740T3 (es) Anticuerpos monoclonales para el receptor del factor de crecimiento de fibroblastos 2
ES2657226T3 (es) Anticuerpo monoclonal anti-VEGF y composición farmacéutica que comprende dicho anticuerpo
ES2527961T3 (es) Anticuerpos monoclonales humanos para CD70
PE20211863A1 (es) Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap
CL2013003373A1 (es) Proteina de union al antigeno de maduración de linfocitos b (bcma); composicion farmacéutica que comprende la proteína; uso para preparar un medicamento util para tratar mieloma multiple o (mm) leucemia linfocitica cronica (cll).
PE20121817A1 (es) Anticuerpos antagonistas anti-notch3
AR065506A1 (es) Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades
PE20211709A1 (es) Anticuerpos que reconocen tau
PE20220279A1 (es) Inhibidores especificos del complejo de ltbp de tgf beta y usos de los mismos
PE20191546A1 (es) Moleculas de union antigeno biespecificas que comprenden el clon 20h4.9 anti-41bb
NZ593853A (en) ANTI-cMET ANTIBODY
PE20231504A1 (es) Anticuerpos especificos para kras y sus usos
NZ585559A (en) Humanized antibodies against tl1a
NZ605980A (en) Anti-fap antibodies and methods of use
NZ578943A (en) Recombinant anti-epidermal growth factor receptor antibody compositions
AR110659A1 (es) Proteínas de unión a antígenos anti-neuropilin y método para su uso
NZ603045A (en) Tnf-alpha binding proteins
NZ596042A (en) Humanized anti-factor d antibodies
ES2570853T3 (es) Moléculas de anticuerpo humanizadas específicas para IL-31
ATE452147T1 (de) Antikörper mit korrigierten cdr
CO6180454A2 (es) Anticuerpos de la egfl7 y metodos de uso
RU2014100111A (ru) МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Psl Pseudomonas, И ПУТИ ИХ ПРИМЕНЕНИЯ
CU20210073A7 (es) Anticuerpos que se unen dentro de la región de unión a microtúbulos de tau definida por cdrs
CO6220841A2 (es) Anticuerpos para linfotoxina-alfa
PE20141547A1 (es) Anticuerpos neutralizantes frente a las exotoxinas principales tcda y tcdb de clostridium difficile